# Gynecologic Cancers Research Program

> **NIH NIH P30** · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2021 · $54,619

## Abstract

GYNECOLOGIC CANCERS PROGRAM – ABSTRACT
The goal of the Gynecologic Cancers (GC) program at the Stephenson Cancer Center (SCC) is to raise the
standard of care and improve clinical outcomes for all women with gynecologic malignancies, with an
emphasis on addressing problems relevant to Oklahoma, the SCC catchment area. Program members
accomplish this goal by conducting transdisciplinary, team-based research that advances discovery of
molecular mechanisms into early- and late-phase randomized trials. The Specific Aims for the GC program
are: (1) to discover and interrogate molecular mechanisms central to carcinogenesis; (2) to investigate
mechanisms underlying cancer therapy response and resistance; and (3) to design and conduct early- and
late-phase randomized clinical trials that advance novel discoveries and improve patient outcomes in the
catchment area and nation.
Highlights of the GC program include: 1) highly interactive basic discovery and clinical members focused on
gynecologic cancers; 2) Specific Aims that organize these program members into focused translational teams,
leading to multi-PI grants and an exceptional rate of intra-programmatic publications; 3) a gynecologic
oncology clinical program that impacts the catchment area by providing multidisciplinary care and access to
clinical trials (58% enrollment rate) for half the new GC cases in Oklahoma; 4) a large annotated biospecimen
bank that supports GC discovery research; 5) active development of GC-focused investigator-initiated trials
and high accrual of GC patients to early-phase novel treatment trials; and 6) national leadership in the design
and conduct of practice-changing NCTN- and Industry-sponsored randomized GC trials.
The GC program has 18 members, representing seven departments, four colleges and two institutions, which
illustrates the transdisciplinary expertise among program members. The translational focus of the program is
reflected in the balance of MD (9) and PhD (9) members. As of December 31, 2016, program members were
awarded $3,865,290 in annual NCI and other peer-reviewed cancer-related support (direct cost). NCI funding
($3,181,558) accounts for 82.3% of the peer-reviewed funding, highlighting the program's cancer focus. Total
annual GC program funding is $8,700,601 (direct cost). For the five-year reporting period (2012-2016), GC
program members published 262 peer-reviewed articles, of which 34.4% included intra-programmatic, 11.8%
included inter-programmatic, and 73.3% included inter-institutional collaborators. For 2016, inter-programmatic
publications were 21.1%, highlighting the increasing number of collaborations underway with the Preclinical
Translational Cancer Research (PTCR) and Cancer Prevention and Control (CPC) programs.

## Key facts

- **NIH application ID:** 10177891
- **Project number:** 5P30CA225520-04
- **Recipient organization:** UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- **Principal Investigator:** DORIS Mangiaracina BENBROOK
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $54,619
- **Award type:** 5
- **Project period:** 2018-05-01 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10177891

## Citation

> US National Institutes of Health, RePORTER application 10177891, Gynecologic Cancers Research Program (5P30CA225520-04). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10177891. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*